TP53 and hepatocellular carcinoma: Unfortunately, most of the mutations in HCC occur in non-druggable pathways such as in the WNT-β-catenin, p53, or the TERT promoter, while those mutations located in more easily treatable targets are only present in a low percentage of patients, making it difficult to apply specific therapies [16,24].